An integrated assessment of ophthalmogeriatric changes in patients with the wet form of agerelated macular degeneration
https://doi.org/10.21516/2072-0076-2022-15-2-supplement-38-43
Abstract
Purpose. Integrated assessment of ophthalmogeriatric changes in patients with the wet form of age-related macular degeneration (AMD) at the time of primary diagnosis.
Material and methods. 200 senior and senile patients aged 60 or more (of which 43.5% were male) with the newly diagnosed wet AMD underwent a standard ophthalmological examination, took a survey aimed at identifying specific risk factors, and tested for Body Mass Index (BMI) and Charlson Comorbidity Index (CCI).
Results. The BMI was 29.46 ± 4.1 kg/m2 and the CCI was 3.3 [2; 4]. The average number of disorders per patient with AMD was 4.0 [2; 6] (ranging from 1 to 7). Polypragmasia took place in 8% of cases. Degenerative changes in the conjunctiva were found in 11%, arcus senilis — in 34.55%, dystrophic changes of the iris — in 68%, pseudoexfoliation syndrome — in 17.5%, senile cataract — in 89.5%, degenerative changes of the vitreous — in 84.5%, primary open-angle glaucoma — in 2% of cases. No gender differences were revealed in these indicators. Among systemic diseases, the most frequent were cardiac and cerebrovascular pathologies (arterial hypertension — 74.5%, ischaemic heart disease — 40.5%, cerebrovascular pathology — 20.5%). Type 2 diabetes mellitus was found in 6.5% of AMD patients.
Conclusion. The wet form of AMD is characterized by a wide range of comorbid disorders that can affect the development and progression of the main disease. Polypragmasia plays its own role in this progression.
About the Authors
A. Y. Brezhnev
Kursk State Medical University
Russian Federation
Russian Federation
Andrey Yu. Brezhnev — Cand. of Med. Sci, associate prof., chair of
ophthalmology
3, Karl Marx St., Kursk, 305041
E. A. Androsova
Kursk State Medical University
Russian Federation
Russian Federation
Elena A. Androsova — PhD student, chair of ophthalmology
3, Karl Marx St., Kursk, 305041
V. I. Baranov
Kursk State Medical University
Russian Federation
Russian Federation
Valery I. Baranov — Dr. of Med. Sci., professor, head of chair of
ophthalmology
3, Karl Marx St., Kursk, 305041
References
1. Kirkwood T.B. A systematic look at an old problem. Nature. 2008; 451 (7179): 644–7. doi: 10.1038/451644a
2. Steves C.J., Spector T.D., Jackson S.H. Ageing, genes, environment and epigenetics: what twin studies tell us now, and in the future. Age Ageing. 2012; 41 (5): 581–6. doi: 10.1093/ageing/afs097
3. Wagner K.-H., Cameron-Smith D., Wessner B., Franzke B. Biomarkers of aging: from function to molecular biology. Nutrients. 2016; 8 (6): 338. doi: 10.3390/ nu8060338
4. Australian Institute of Health and Welfare (AIHW): Chronic diseases and associated risk factors in Australia. Canberra, ACT; 2006.
5. Hoel R., Connolly R., Takahashi P. Polypharmacy management in older patients. Mayo Clin. Proc. 2021; 96 (1): 242–56. doi: 10.1016/j.mayocp.2020.06.012
6. Bourne R., Steinmetz J., Flaxman S., et al. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. The Lancet Global Health. 2021; 9 (2): e130-e143. doi: 10.1016/S2214-109X(20)30425-3
7. Klein R., Klein B. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Invest. Ophthalmol. Vis. Sci. 2013; 54 (14): ORSF5-ORSF13. doi: 10.1167/iovs.13-12789
8. Munz I.V., Direev A.O., Gusarevich O.G., et al. Prevalence of ophthalmic diseases in the population older than 50 years. Vestnik oftal’mologii. 2020; 136 (3): 106–15 (in Russian). doi: 10.17116/oftalma2020136031106
9. Saldanha I.J., Lindsley K., Do D.V., et al. Comparison of clinical trial and systematic review outcomes for the 4 most prevalent eye diseases. JAMA Ophthalmol. 2017; 135 (9): 933–40. doi: 10.1001/jamaophthalmol.2017.2583
10. Deng Y., Qiao L., Du M. et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2021; 9 (1): 62–79. doi: 10.1016/j.gendis.2021.02.009
11. Cheung C., Wong T. Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment. Journal of Internal Medicine. 2014; 276 (2): 140–53. doi: 10.1111/joim.12227
12. Ministry of Health of the Russian Federation. Clinical recommendations “Age related macular degeneration”, 2021 (in Russian). Available at: https://cr.minzdrav. gov.ru/recomend/114_2
13. Age-Related Eye Disease Study Research Group. A randomized, placebocontrolled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001; 119 (10): 1417-36. doi: 10.1001/ archopht.119.10.1417
14. Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J. Clin. Epidemiol. 1994; 47 (11): 1245–51. doi: 10.1016/0895-4356(94)90129-5
15. Wang Y., Zhong Y., Zhang., et al. Global incidence, progression, and risk factors of age-related macular degeneration and projection of disease statistics in 30 years: a modeling study. Gerontology. 2021: 1–15. doi: 10.1159/000518822
16. Chakravarthy U., Wong T.Y., Fletcher A., et al. Clinical risk factors for agerelated macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010; 10: 31. doi: 10.1186/1471-2415-10-31
17. Lambert N., El-Shelmani H., Singh M., et al. Risk factors and biomarkers of age-related macular degeneration Prog. Retin. Eye Res. 2016; 54: 64–102. doi: 10.1016/j.preteyeres.2016.04.003
18. Fabbri E., Zoli M., Gonzalez-Freire M., et al. Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. J. Am. Med. Dir. Assoc. 20151; 16 (8): 640–7. doi: 10.1016/j.jamda.2015.03.013
19. Grossniklaus H., Nickerson J., Edelhauser H., Bergman L., Berglin L. Anatomic alterations in aging and age-related diseases of the eye. Invest. Ophthalmol. Vis. Sci. 2013; 54 (14): ORSF23-7. doi: 10.1167/iovs.13-12711
20. Vortkin A.L., Rumyantsev M.A., Skotnikov A.S. Comorbidity. Klinicheskaya meditsina. 2012; 90 (10): 4–11 (in Russian)
21. Konyaev D.A. Polymorbid and ophthalmological status of middle-aged and elderly patients with age-related macular degeneration Sovremennye problemy zdravoohranenija i medicinskoj statistiki. 2020; 3: 428–41 (in Russian). doi: 10.24411/2312-2935-2020-00084
22. Smith W., Mitchell P., Wang J.J. Gender, oestrogen, hormone replacementand age-related macular degeneration: results from the Blue Mountains Eye Study. Aust. N .Z. J. Ophthalmol. 1997; 25 Suppl 1: S13–5. doi: 10.1111/j.1442- 9071.1997.tb01745.x
23. Rudnicka A.R., Jarrar Z., Wormald R., et al. Ageand gender variations in agerelated macular degeneration prevalence inpopulations of European ancestry: a meta-analysis. Ophthalmology. 2012; 119 (3): 571–80. doi: 10.1016/j. ophtha.2011.09.027
24. Zetterberg M. Age-related eye disease and gender. Maturitas. 2016; 83: 19–26. doi: 10.1016/j.maturitas.2015.10.005
25. Ritch R., Schl tzer-Schrehardt U. Exfoliation syndrome. Surv. Ophthalmol. 2001; 45 (4): 265–315. doi: 10.1016/s0039-6257(00)00196-x
26. Scharfenberg E., Rauscher F.G., Meier P., Hasenclever D. Pseudoexfoliation syndrome: analysis of systemic comorbidities of 325 PEX-positive patients compared with 911 PEX-negative patients. Graefes Arch. Clin. Exp. Ophthalmol. 2019; 257 (11): 2471–80. doi: 10.1007/s00417-019- 04438-4
27. Zengin M.O., Karti O., Karahan E., Kusbeci T. An evaluation of the relationship between clinically unila teral pseudoexfoliation syndrome and age-related macular degeneration. Ophthalmic Surg. Lasers Imaging Retina. 2018; 49 (1): 12–9. doi: 10.3928/23258160-20171215-02
28. Kozobolis V.P., Detorakis E.T., Tsilimbaris M.K., et al. Correlation between age-related macular degeneration and pseudoexfoliation syndrome in the population of Crete (Greece). Arch. Ophthalmol. 1999; 117 (5): 664–9. doi: 10.1001/archopht.117.5.664
29. Potemkin V.V., Astakhov S.Yu., Xiaoyuan Wang, et al. The influence of pseudoexfoliation syndrome on central retina in elderly patients. Uspehi gerontologii. 2021; 34 (2): 258–63 (in Russian). doi: 10.34922/AE.2021.34.2.011
30. Baranov V.I., Brezhnev A.Yu. Pseudoexfoliation syndrome in Central Russia: a clinical and epidemiological study. Russian ophthalmologicaljournal. 2012; 5 (1): 22–4 (in Russian).
31. Hu C.C., Ho J.D., Lin H.C., Kao L.T. Association between open-angle glaucoma and neovascular age-related macular degeneration: a case-control study. Eye (Lond). 2017; 31 (6): 872–7. doi: 10.1038/eye.2016.325
32. Avdeev R.V., Alexandrov A.S., Basinsky A.S., et al. Multicentre study of morphofunctional status of visual analyzer in simultaneous presence in eye glaucoma and age-related macular degeneration with determination of correlations and connections. Ophthalmology. Eastern Europe. 2013; 4 (19): 15–25 (in Russian).
33. Chen X., Rong S.S., Xu Q., et al. Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis. PLoS One. 2014; 9 (9): e108196. doi: 10.1371/journal.pone.0108196
Review
For citations:
Brezhnev A.Y., Androsova E.A., Baranov V.I. An integrated assessment of ophthalmogeriatric changes in patients with the wet form of agerelated macular degeneration. Russian Ophthalmological Journal. 2022;15(2 (Прил)):38-43. (In Russ.) https://doi.org/10.21516/2072-0076-2022-15-2-supplement-38-43
Views:
509
Email this article 